InSite Vision Incorporated (OTCBB: INSV) today announced that Timothy Ruane, InSite’s Chief Executive Officer will provide a corporate presentation at the 25 th Annual ROTH Conference on Wednesday, March 20, 2013 at 12:00 pm PT at the Ritz Carlton Hotel in Dana Point, CA. A webcast of the presentation will be accessible on the Investor section of InSite Vision’s website at www.insitevision.com and will be available for 30 days following the event. About InSite Vision InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite ® platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite ® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance ® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus ™ and DexaSite ™ for the treatment of eye infections, and BromSite™ for pain and inflammation associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com. AzaSite ®, DuraSite ® and DuraSite 2 ® are registered trademarks of InSite Vision Incorporated. AzaSite Plus ™, BromSite ™ and DexaSite ™ are trademarks of InSite Vision Incorporated. BESIVANCE ® is a registered trademark of Bausch + Lomb Incorporated.